The conference call will be accessible by dialing 844-348-3946 (toll-free domestic) or 213-358-0892 (international callers) using the access code: 8569879.
Fourth quarter and full year 2018 financial results discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at http://news.reatapharma.com and will be available for 12 months after the call. The audio recording will be accessible for at least 90 days after the event through the Investors section of the company’s website at http://reatapharma.com.
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling.
Vice President, Strategy
Matt Middleman, M.D.
LifeSci Public Relations
Source: Reata Pharmaceuticals, Inc.